Plus-end-directed organelle transport along microtubule

Across TCGA pan-cancer cohorts, RNA activity of the Plus-end-directed organelle transport along microtubule pathway differs between tumor and matched normal tissue in 6 of the 18 cancer types tested.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where pathway activity is lower in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LIHC and COAD, show the opposite pattern, with lower activity in tumor tissue.

LIHC, COAD, and KICH show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
LIHC	Male	II,III,IV	−0.055	<.001	8	view →
COAD	Female	II,III,IV	−0.052	<.001	6	view →
KICH	Male	All	−0.061	.001	4	view →
LUSC	All	All	−0.027	.001	4	view →
KIRP	Male	All	−0.046	.001	2	view →
KIRC	Male	All	−0.020	.030	2	view →

Pink = more active in tumor, green = less active in tumor. Showing the 6 strongest of 6 lineages.

GO:0072386–LIHC

Open the LIHC breakdown →